Compare TG Therapeutics Inc (TGTX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs ProShares UltraPro S&P500 — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while ProShares UltraPro S&P500 trades at $154.66. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | UPRO | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $59.06 | $155.10 |
52-Week Low | $26.94 | $89.29 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
UPRO trades at $154.55, down 0.28% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF shows strong institutional interest with Bay Colony Advisors establishing a new position. Market sentiment is mixed as the S&P 500 faces valuation concerns at record highs, with the Fear & Greed index indicating greed zone conditions amid inflation data anticipation.
The leveraged ETF's performance remains tied to S&P 500 momentum, with technical support at $150-$152 providing downside protection. Key risks include market volatility and overbought conditions, while institutional accumulation suggests confidence in near-term upside potential despite broader market valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
